Find clinical trials for Non-Hodgkin Lymphoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma trials near Nashville, TN, USA:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...

Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1


Nashville, Tennessee, United States and 7 other locations

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3


Nashville, Tennessee, United States and 66 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Nashville, Tennessee, United States and 73 other locations

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

Nashville, Tennessee, United States and 26 other locations

administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) admin...

Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: CFT7455

Phase 1, Phase 2

C4 Therapeutics

Nashville, Tennessee, United States and 12 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Nashville, Tennessee, United States and 29 other locations

in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The...

Non-Hodgkin Lymphoma
Relapsed Solid Tumors
Drug: KB-0742

Phase 1, Phase 2

Kronos Bio

Nashville, Tennessee, United States and 25 other locations

A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin...

Diffuse Large B Cell Lymphoma (DLBCL)
Biological: bbT369

Phase 1, Phase 2

2seventy bio

Nashville, Tennessee, United States and 3 other locations

This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...

Active, not recruiting
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma
Biological: axicabtagene ciloleucel
Drug: Fludarabine

Phase 2

Gilead Sciences
Gilead Sciences

Nashville, Tennessee, United States and 18 other locations

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

Nashville, Tennessee, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems